The role of inflammatory parameters in predicting disease recurrence in patients with stage IIA colon cancer with no high-risk features

• DOI: 10.1080/00325481.2021.1934493
• Publication Date: 2021-05-25T08:26:41Z
• Authors: Erkan Erdur; Ozgen Ahmet Yildirim; Kerem Poyraz; Ferit Aslan; Fatih Yıldız; Halil Kömek
• Keywords: Inflammation; Male; Neutrophils; Middle Aged; Prognosis; Risk Assessment; 3. Good health; Leukocyte Count; 03 medical and health sciences; C-Reactive Protein; 0302 clinical medicine; Predictive Value of Tests; Risk Factors; Colonic Neoplasms; Humans; Female; Lymphocytes; Neoplasm Recurrence, Local; Serum Albumin; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies

We aimed to investigate the roles of inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), and C-reactive protein/albumin ratio (CAR), in predicting disease recurrence in patients with stage IIA (T3N0M0) high microsatellite instability and microsatellite-stable colon cancer who had no risk factors associated with relapse.We evaluated 155 patients with colon cancer followed in 3 hospitals in Turkey between February 2009 and March 2020. These patients had stage IIA disease and had no risk factors associated with relapse. None of the patients received adjuvant chemotherapy. NLR, PLR, LMR, and CAR parameters were retrospectively obtained from laboratory results at the time of diagnosis, and their associations with disease recurrence were assessed.Over a median follow-up period of 38 months (range: 4-98 months), 11 of the 155 patients experienced relapse or developed metastases. Multivariate Cox analyses revealed that NLRs of ≥3.12 (hazard ratio [HR]: 0.041, 95% confidence interval [CI]: 0.048-0.826, p = 0.006) and CARs of ≥0.027 (HR: 0.199, 95% CI: 0.004-0.404, p = 0.026) were independent prognostic markers predicting relapse. The median 5-year recurrence-free survival rate of patients with NLRs of ≥3.12 at the time of diagnosis was 88.0%; this rate was 100% in patients with NLRs of <3.12 (p < 0.001). Similarly, the median 5-year recurrence-free survival rate of patients with CARs of ≥0.027 at the time of diagnosis was 84.7%; this rate was 95.7% in patients with CARs of <0.027 (p = 0.016).In this study, NLR and CAR were found to be independent prognostic markers predicting disease recurrence in patients with stage IIA colon cancer who did not receive adjuvant chemotherapy due to low clinical risk.